Skip to main content
. 2020 Dec;190(12):2355–2375. doi: 10.1016/j.ajpath.2020.08.018

Figure 6.

Figure 6

Platelets, fibrin, and macrophages in lungs after bleomycin challenge. A–F: Low-magnification images of lungs comparing little or no staining for platelets (red; CD41) or fibrin (green; antifibrinogen/fibrin) at baseline (no bleomycin; A–C) with widespread staining for both at 7 days after bleomycin treatment (D–F), a stage in disease progression before much lymphangiogenesis has occurred. G–I: Higher-magnification images showing lymphatics (cyan) near overlapping deposits of platelets and fibrin. J: Wet lung weight (both lungs). Dots represent individual mice. Blue dots, baseline (no bleomycin); black dots, 14-day bleomycin. K–M: Macrophages (red) and prospero homeobox 1-enhanced green fluorescent protein (Prox1-EGFP) (green) in lymphatics and cardiac muscle of large pulmonary veins at 0, 7, and 28 days after bleomycin administration. K: Macrophages scarce at baseline. L: Increase in number 7 days after bleomycin treatment, preceding lymphatic growth. M: Macrophages coincident with regions of lymphatic growth at 28 days. n = 5 mice per group (J). ∗P < 0.05 versus baseline (t-test). Scale bars: 1 mm (A–F and K–M); 50 μm (G–I). Aif1/Iba1, allograft inflammatory factor 1/ionized calcium binding adapter molecule 1.